Screener
Spyre Therapeutics, Inc. SYRE Business Segments — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Spyre Therapeutics, Inc.’s 10-K, filed February 19, 2026.
- Filed
- Feb 19, 2026, 4:01 PM EST
- Fiscal year
- FY2025
- Accession
- 0001636282-26-000020
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Revenue | — | — | $886 |
| Less: | |||
| Compensation | $34,794 | $21,780 | $22,590 |
| Stock-based compensation (1) | 37,614 | 44,833 | 25,675 |
| Research and development, excluding compensation and stock-based compensation (2) (3) | 132,490 | 127,491 | 65,282 |
| Other segment items (4) (5) | (49,695) | 13,914 | 226,129 |
| Segment net loss | $155,203 | $208,018 | $338,790 |
| Reconciliation of net loss |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Spyre Therapeutics, Inc.'s business segments — total revenue?
- Spyre Therapeutics, Inc. (SYRE) reported business segments — total revenue of $0 in Q4 2025.
- What is the long-term trend for Spyre Therapeutics, Inc.'s business segments — total revenue?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s business segments — total revenue has grown at a -100.0% compound annual growth rate (CAGR), from $2.33M to $0.
- What does business segments — total revenue mean?
- The total gross income generated by the segment from its primary business activities, such as licensing agreements, product sales, or research collaborations. It serves as the top-line indicator of the segment's market traction.
Ask your AI about Spyre Therapeutics, Inc.'s business segments — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude